We are thrilled to have participated in the final meeting of the OA-BIO consortium, marking the culmination of several years of groundbreaking collaboration with our partnerships, Chondrometrics GmbH, Universiteit Utrecht, and AO Research Institute Davos (ARI).

Together, we've made remarkable strides in advancing our project, 4P004, towards a Phase IIA clinical trial. Our work has been driven by a cutting-edge, biomarker-based approach as part of the EUREKA-Eurostars Horizon 2020 European research framework.

‍